The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents β-lactam antibiotic resistance, but with the same safe and
Proceeds will be used to advance the company’s portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections. In connection with the financing, Versant Partner Carlo
The litigation related primarily to allegations that Celgene promoted Thalomid (thalidomide) for off-label uses before its 2006 FDA approval for newly diagnosed multiple myeloma. The Department of Justice,
"This is a great result for the Mitchell family and all the other victims of AbbVie's fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears
NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory
In a release, Bayer's partner MorphoSys stated that anetumab ravtansine is an antibody-drug conjugate (ADC) directed against mesothelin, consisting of an antibody made using MorphoSys’s HuCAL technology. Malignant pleural
The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution
In a study released today in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer’s drug “galantamine” cut key markers of inflammation – a hallmark of metabolic
The FDA approval marks the first subcutaneous self-injection treatment option for patients with SLE, the most common form of lupus – a chronic, incurable autoimmune disease producing autoantibodies
The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel, potent, and selective JAK1 inhibitor, in combination with corticosteroids compared to placebo plus corticosteroids in patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.